Q32 Bio presented encouraging 36-week and 16-week off-drug results from its Phase 2a SIGNAL-AA trial of bempikibart, a treatment for severe alopecia areata (AA), showing durable and deepening hair regrowth. The data supports less frequent chronic dosing and the company plans to start a Phase 3 registration-directed program in the first half of 2027, pending regulatory discussions. Q32 Bio also strengthened its leadership team and ended Q3 2026 with $289.6 million in cash, enough to fund operations through Phase 3 topline results. The ongoing open-label extension will provide further data on long-term maintenance dosing.
Q32 Bio's recent financial update coincides with a Health sector where 95 of 150 US stocks rose as of Nov 04, 2026 18:01 WIB. For readers following Health-sector stocks on Pluang, here is the market snapshot: Tilray Brands Inc (TLRY) rose 5.28% to USD 2.79 with 96% sell orders, Centene Corp (CNC) gained 4.77% to USD 70.70, and Recursion Pharmaceuticals Inc (RXRX) increased 4.35% to USD 3.84 with 100% buy orders. Typical hold times ranged from 22 to 43 days across these movers.
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
